Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Schenk

Showing results (61-70 of 102) with videos related to

Pageof 11
Sort By:
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|January 4, 2019
[Empirical health services research in emergency and acute medicine : Preliminary results of concomitant monitoring of patient recruitment and sample quality]V Krobisch, J Deutschbein, M Möckel, et al.
JTO Clinical and Research Reports|August 13, 2025
Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase InhibitorsAlexander S Watson, Alyse W Staley, Benjamin Yoder, et al.
Cell Death and Differentiation|January 14, 2017
The BCL-2 pro-survival protein A1 is dispensable for T cell homeostasis on viral infectionSelma Tuzlak, Robyn L Schenk, Ajithkumar Vasanthakumar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 11, 2020
Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib InitiationTerry L Ng, Amber Johnson, Raphael A Nemenoff, et al.
Advances in Radiation Oncology|June 13, 2024
The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung CancerDavid Chun Cheong Tsui, Douglas E Holt, Tejas Patil, et al.
JTO Clinical and Research Reports|August 18, 2025
Role of Quality of Life in Daily Functioning, Communication with Care Teams, and Treatment Decisions in Patients with <i>ALK</i>+ NSCLCHeather Law, Huamao M Lin, Eileen Curran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2025
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3Natasha B Leighl, Nofisat Ismaila, Greg Durm, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2008
Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivoSuresh Radhakrishnan, Rosalyn Cabrera, Erin L Schenk, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung CancerJacob Langston, Tejas Patil, D Ross Camidge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1Lyudmila Bazhenova, Nofisat Ismaila, Greg Durm, et al.
Pageof 11

Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|January 4, 2019
[Empirical health services research in emergency and acute medicine : Preliminary results of concomitant monitoring of patient recruitment and sample quality]V Krobisch, J Deutschbein, M Möckel, et al.
JTO Clinical and Research Reports|August 13, 2025
Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase InhibitorsAlexander S Watson, Alyse W Staley, Benjamin Yoder, et al.
Cell Death and Differentiation|January 14, 2017
The BCL-2 pro-survival protein A1 is dispensable for T cell homeostasis on viral infectionSelma Tuzlak, Robyn L Schenk, Ajithkumar Vasanthakumar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 11, 2020
Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib InitiationTerry L Ng, Amber Johnson, Raphael A Nemenoff, et al.
Advances in Radiation Oncology|June 13, 2024
The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung CancerDavid Chun Cheong Tsui, Douglas E Holt, Tejas Patil, et al.
JTO Clinical and Research Reports|August 18, 2025
Role of Quality of Life in Daily Functioning, Communication with Care Teams, and Treatment Decisions in Patients with <i>ALK</i>+ NSCLCHeather Law, Huamao M Lin, Eileen Curran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2025
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3Natasha B Leighl, Nofisat Ismaila, Greg Durm, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2008
Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivoSuresh Radhakrishnan, Rosalyn Cabrera, Erin L Schenk, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung CancerJacob Langston, Tejas Patil, D Ross Camidge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1Lyudmila Bazhenova, Nofisat Ismaila, Greg Durm, et al.
Pageof 11